Mrs Ping Cannon
Research Assistant- Translational Obstetrics Group
Department of Obstetrics, Gynaecology and Newborn Health
94 Scholarly works
0 Projects
HIGHLIGHTS
2026
Journal article
Thrombospondin-1 (THBS1) is dysregulated in preeclampsia
DOI: 10.1016/j.placenta.2025.11.0132025
Journal article
Plasma proteomics can identify associations between pregnancy complications and future health risks.
DOI: 10.1016/j.placenta.2025.08.1492025
Journal article
Trophoblast Receptor Landscape Reveals a Paracrine Role for Syncytiotrophoblast-Derived Activin A in Early Placental Development
DOI: 10.1016/j.placenta.2025.08.0152025
Journal article
Correction to: Stem Cell Markers LGR5, LGR4 and Their Immediate Signalling Partners are Dysregulated in Preeclampsia (Stem Cell Reviews and Reports, (2025), 21, 3, (872-896), 10.1007/s12015-024-10831-2)
DOI: 10.1007/s12015-025-10980-y2025
Journal article
Ingenol Mebutate as a Novel Therapeutic Candidate for preeclampsia.
DOI: 10.1016/j.placenta.2025.08.2942025
Journal article
The association between circulating SIGLEC6 and preeclampsia: observational studies of seven cohorts
DOI: 10.1016/j.ebiom.2025.1058702025
Journal article
Reduced circulating NrCAM as a biomarker for fetal growth restriction
DOI: 10.1016/j.ebiom.2025.105854
RECENT SCHOLARLY WORKS
2025
Journal article
Alpha-fetoprotein (AFP) is reduced at 36 weeks’ gestation in pregnancies destined to deliver small for gestational age infants
DOI: 10.1016/j.ejogrb.2025.03.0272025
Journal article
Stem Cell Markers LGR5, LGR4 and Their Immediate Signalling Partners are Dysregulated in Preeclampsia
DOI: 10.1007/s12015-024-10831-22025
Journal article
Cystatin 6 (CST6) and Legumain (LGMN) are potential mediators in the pathogenesis of preeclampsia
DOI: 10.1038/s41598-025-96823-9